Background The combination of docetaxel, cisplatin, and 5-fluorouracil (DCF) is an effective but highly toxic regimen for the treatment of advanced gastric cancer. To improve tolerability while maintaining the efficacy of the DCF regimen, we developed a modified DCF regimen including an infusional 5-fluorouracil administration according to the de Gramont regimen. Methods In this study, 70 patients with advanced gastric cancer were treated. Each 2-week cycle consisted of docetaxel (60 mg/m 2 ), cisplatin (50 mg/m 2 ), a 5-fluorouracil (400 mg/m 2 ) IV bolus, and 5-fluorouracil (2,400 mg/m 2 ) IV over 46 h plus leucovorin (400 mg/m 2 ) IV over 2 h. Results The median progression-free survival and overall survival were 9.0 months (95 % CI, 7.1-10.9) and 10.8 months (95 % CI, 7.4-14.2), respectively; the 1-year and 2-year overall survival rates were 46.3 and 18.4 %, respectively. Twenty-nine (41.4 %) partial responses, 19 (27.1 %) stable disease, and 22 (31.4 %) progression of disease were observed. Grade 3-4 toxicities included neutropenia (37.1 %), febrile neutropenia (15.7 %), thrombocytopenia (10.0 %), anemia (8.6 %), nausea and vomiting (10.0 %), stomatitis (5.7 %), infection (8.6 %), and diarrhea (2.9 %).
Introduction
Gastric cancer remains one of the leading causes of cancer mortality worldwide [1] . In the treatment of advanced gastric cancer (AGC), no chemotherapy combination was accepted as the gold standard. Cisplatin plus 5-fluorouracil (CF) and epirubicin plus CF (ECF) regimens have been investigated widely in clinical studies and were, until recently, presented as the reference regimens [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . The activity of docetaxel in gastric cancer was first demonstrated in phase II single-agent studies: reported overall response rates (ORRs) were 16-24 % in the first-line setting [13] [14] [15] [16] [17] . The combination of docetaxel and cisplatin (DC) as a first-line chemotherapy was revealed to have a modest anti-tumor effect and manageable toxicity for the palliative treatment of AGC [18] [19] [20] .
A phase I/II dose-finding study demonstrated the feasibility of adding a protracted continuous infusion of 5-fluorouracil (5-FU) to DC (DCF) [21] . The subsequent three-arm, randomized, phase II study was conducted to compare firstline ECF, DC, and DCF regimens in patients with AGC. The results demonstrated ORRs of 25.0, 18.5, and 36.6 % for ECF, DC, and DCF, respectively, and median survival durations of 8.3, 11.0, and 10.4 months, respectively [22] .
In patients with AGC, the DCF triplet regimen appeared to be superior in terms of response rate to the doublet regimen of DC [23] . The subsequent phase III V325 trial was a randomized trial of first-line DCF versus CF in patients with AGC. This study showed that adding docetaxel to CF significantly improved progression-free survival (PFS) (5.6 months), overall survival (OS) (9.2 months), 1-year survival (40 %), 2-year survival (18 %), and ORR (37 %) compared with CF [24] . Despite a higher incidence of some toxicities as a result of the addition of docetaxel to CF, the quality-of-life results of the V325 trial consistently favored DCF over CF, supporting the benefit of DCF [25] . Following the results of the V325 trial, the DCF has become a new reference regimen in AGC [3, 13] . However, the toxicity profile of the DCF regimen has contributed to the limitations of using this combination. To improve tolerability while maintaining efficacy, several variations of the DCF regimen have either been reported or are currently under investigation, with different doses and administration schedules.
A bimonthly 2-day combination of leucovorin (LV) and 5-FU bolus plus continuous infusion (de Gramont regimen) permits a twofold increase in the dosage of 5-FU with less toxicity than the LV-5-FU bolus protocols, and this regimen increases the response rate in patients with colorectal carcinoma [26, 27] . The de Gramont regimen has also been investigated for the treatment of AGC either alone [28] , in combination with cisplatin [29, 30] , in combination with irinotecan [30, 31] , in combination with cisplatin plus mitomycin-C [32] , in combination with cisplatin plus epirubicin [33] , or in combination with docetaxel plus cisplatin [34, 35] . The results of these trials were encouraging in terms of both the safety profile and the activity.
In this study, we combined the de Gramont regimen with docetaxel and cisplatin, which was repeated every 2 weeks (modified DCF). The administration of the de Gramont regimen in combination with docetaxel and cisplatin has been previously reported by Tomasello et al. and Shah et al. [34, 35] , but with only one 5-FU bolus, and a 46-h infusion of 5-FU in combination with cisplatin and docetaxel has not been previously reported. This study was planned to analyze the efficacy, toxicity, and convenience of a de Gramont-based DCF regimen as a first-line treatment in a larger number of patients with AGC. 2 ) IV with hydration on day 1, 5-FU (400 mg/m 2 ) IV bolus, and 5-FU (2,400 mg/m 2 ) IV over 46 h plus LV (400 mg/m 2 ) IV over 2 h on day 1. A permanent venous access (port system) was implanted to enable a continuous infusion of 5-FU. For the prevention of chemotherapy-induced neutropenia, the patients were prophylactically administered a subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at a dose of 5 lg/kg on days 3, 4, 5, 6, and 7. Treatment was repeated every 2 weeks until disease progression, patient refusal, or unacceptable adverse reactions occurred. All patients were fully informed regarding the treatment.
Patients and methods

We
All the patients underwent a strict follow-up every 3 months. Before each cycle of chemotherapy, a complete blood count, blood urea nitrogen, electrolyte, and serum creatinine levels were obtained and liver function was determined. Dose reductions and delays of the mDCF regimen were implemented for patients with toxicities. The severity of the adverse effects was defined according to the National Cancer Institute Common Toxicity Criteria (NCI CTC). Toxicity from the chemotherapy was recorded by using hematological and biochemical parameters and by performing regular patient interviews. The medical records of these patients were retrospectively reviewed; the response evaluations and the side effects of the chemotherapy regimen were recorded. Response to treatment, defined by the Response Evaluation Criteria In Solid Tumors (RECIST), was evaluated by repeated computed tomography imaging every six cycles or earlier if clinically indicated. Doses of all drugs were reduced by 20 % in subsequent cycles in the case of grade 3-4 hematological toxicities or grade 3-4 stomatitis or grade 3-4 nausea and vomiting. Doses of docetaxel and 5-FU were reduced by 20 % in case of grade 3-4 diarrhea. Administration of cisplatin was stopped in case of grade C2 peripheral neuropathy and grade C2 nephrotoxicity where the glomerular filtration rate was less than 50 % of the lower limit of normal. The administration of chemotherapy was delayed until neutrophils recovered (C1,500/mm 3 ) or platelets reached C100,000/mm 3 , or until resolution of any significant nonhematological toxicity. Treatment was interrupted for a recurrent grade 3-4 toxicity despite dose reduction.
Progression-free survival was defined as the time interval from the start of chemotherapy to the date of disease progression. Overall survival was calculated from the first day of treatment to death or the date of the last follow-up. Statistical analyses were performed with an SPSS program Modified DCF in advanced gastric cancer 429
for Windows (version 15.0). The Kaplan-Meier method was used to estimate PFS and OS. P values of 0.05 or less were considered statistically significant.
Results
Patient characteristics are listed in Table 1 . The median age was 53.5 years (range, 33-74 years), with a male predominance (68.6 %). Sixty-three patients (90.0 %) had performance status 0 or 1. Fifty-five patients (78.6 %) had metastatic disease at first diagnosis; the rest had recurrent disease. Ten patients (14.3 %) had received prior adjuvant chemotherapy. Six hundred and thirty-two cycles of chemotherapy were administered with a median of 10 cycles, ranging from 2 to 18 cycles. The most common disease sites were lymph nodes (48.6 %), peritoneum (47.1 %), liver (42.9 %), and lung (14.3 %).
Of the 632 cycles administered, dose reduction for at least one infusion was implemented for 33 patients (47.1 %) because of grade 3-4 toxicity, and dose delays were necessary in 40 patients (57.1 %). The toxicity profile is summarized in Table 2 . The most common toxicities were hematological and gastrointestinal. Grade 3-4 neutropenia developed in 26 patients (37.1 %), and febrile neutropenia occurred in 11 patients (15.7 %). Seven patients (10.0 %) had grade 3-4 thrombocytopenia, and 6 patients (8.6 %) had anemia. The most commonly reported grade 3-4 gastrointestinal toxic effects were nausea and vomiting (10.0 %). Other nonhematological grade 3-4 toxicities included stomatitis (5.7 %), infection (8.6 %), and diarrhea (2.9 %). Cisplatin was discontinued in 1 patient because of grade 2 peripheral sensorial neuropathy and in 2 patients because of grade 2 nephrotoxicity. Docetaxel was discontinued in 1 patient for grade 2 skin toxicity. The treatment was interrupted in 12 patients (17.1 %) because of treatment-related toxic effects. Four deaths (5.7 %) occurred within 30 days of the last infusion. The main causes of treatment-related deaths were myocardial infarction (MI) in 3 patients and pneumonia in 1 patient.
Response rates with mDCF regimen are shown in Table 3 . Twenty-nine (41.4 %) partial responses, 19 (27.1 %) stable disease, and 22 (31.4 %) progression of disease were observed. No complete response was recorded. The median progression-free survival time was 9.0 months [95 % confidence interval (CI), 7.1-10.9] and the 1-year and 2-year progression-free survival rates were 32.8 and 11.2 %, respectively (Fig. 1) . The median overall survival time was 10.8 months (95 % CI, 7.4-14.2) and the 1-year and 2-year overall survival rates were 46.3 and 18.4 %, respectively (Fig. 2) . Twenty-one patients (30.0 %) received second-line chemotherapy after failure of this regimen. Of the 21 patients who received secondline chemotherapy, 17 patients received irinotecan-based chemotherapy and 4 patients received etoposide-based chemotherapy. During the study period, a total of 48 patients (68.6 %) have died.
Discussion
In light of the substantial toxicity of the DCF regimen, various attempts have been made to lessen its toxicity by modifying its dose and schedule. Herein, we investigated the de Gramont-based modified DCF regimen with the goal of minimizing toxicity without compromising efficacy. Our regimen demonstrated reasonable activity, with an ORR of 41.4 %, and a rate of stable disease of 27.1 %. The median PFS and OS were 9.0 and 10.8 months, respectively; the 1-year and 2-year overall survival rates were 46.3 and 18.4 %, respectively. The survival rates in our series were similar to those previously reported among patients with AGC using the standard DCF [24, 36] . In the V325 trial, the median PFS and OS for DCF regimen were 5.6 and 9.2 months, respectively; the 1-year and 2-year survival rates were 40 and 18 %, respectively, with an ORR of 37 %.
In that study, grade 3-4 neutropenia and febrile neutropenia were observed in 82 and 29 % of patients, respectively. The chemotherapy regimen in our study was generally well tolerated. We have found that our mDCF regimen has a better toxicity profile when compared to the standard DCF regimen [24, 36] . In our study, we observed grade 3-4 neutropenia in 37.1 % of patients and febrile neutropenia in 15.7 % of patients. However, despite the promising safety data in our study, dose delays and dose reductions of one to two agents were required in 57.1 and 47.1 % of patients, respectively. Considering that the complete blood count was done before each cycle in our study, the rate of neutropenia that usually appears after 7 days of docetaxel treatment could be higher than detected. The number of deaths occurring within 30 days of the last infusion was 4 (5.7 %) in our study and 23 (10 %) in the V325 trial with the standard DCF regimen [24] . The main cause of toxic deaths was infection in the V325 trial. In our study, the rate of grade 3-4 neutropenia, febrile neutropenia, and grade 3-4 infection was lower than in the V325 trial since we administered prophylactic G-CSF. The common features of the three patients lost by MI in our study were existence of peritoneal metastasis and grade 3-4 nausea/vomiting associated with chemotherapy. We thought that hypovolemia, which occurred in the patients because of grade 3-4 nausea/vomiting, might induce MI. In addition, we thought that diffuse lung metastases and grade 3-4 neutropenia in the patient who died of pneumonia might have contributed to that patient's death.
The DCF regimen used by Roth et al. consisted of docetaxel (75 mg/m 2 ) and cisplatin (75 mg/m 2 ) on day 1, plus protracted continuous infusion of 5-FU at a dose of 300 mg/m 2 /day as a continuous infusion on days 1 to 14, every 3 weeks [22] . In their study, the median OS was 10.4 months and ORR was 36.6 %. They observed grade 3-4 neutropenia and febrile neutropenia in 80 and 41 % of patients, respectively. When compared to the DCF regimen with protracted infusion of 5-FU used by Roth et al., our de Gramont-based DCF regimen appears considerably more tolerable without compromising efficacy. Tomasello et al. conducted a phase II trial in 32 patients with AGC to evaluate for the first time the feasibility and activity of a modified DCF regimen, including an infusional 5-FU administration according to the de Gramont schedule [34] . This regimen consisted of docetaxel (85 mg/m 2 ) on day 1, cisplatin (75 mg/m 2 ) on day 1, LV (100 mg/m 2 ) on days 1 and 2, followed by 5-FU (400 mg/m 2 ) IV bolus on days 1 and 2, and then 5-FU (600 mg/m 2 ) IV in continuous infusion of 22 h, on days 1 and 2, every 2 weeks [34] . In their study, the most frequent grade 3-4 toxicities were neutropenia (53 %), thrombocytopenia (34 %), anemia (16 %), febrile neutropenia (22 %), asthenia (38 %), and diarrhea (19 %). The median PFS and OS were 9.1 and 10.1 months, respectively [34] . These researchers concluded that a dose-dense DCF regimen in AGC that was repeated every 2 weeks seems to be feasible, with activity comparable to previous results achieved with epirubicinbased chemotherapy and standard DCF regimens which were repeated every 3 weeks [22, 24] .
As did Tomasello et al., Shah et al. also reported the de Gramont-based DCF regimen in 41 patients with AGC [35] . In that study, patients were randomly assigned to Arm A: de Gramont-based DCF (docetaxel 40 mg/m 2 , 5-FU 400 mg/m 2 , LV 400 mg/m 2 , 5-FU 1,000 mg/m 2 /day on days 1 and 2, cisplatin 40 mg/m 2 on day 3, every 2 weeks), or Arm B: standard DCF [35] . The response rate of Arm A versus Arm B was 52 versus 34 %, respectively. The PFS was 8.6 months versus 7.1 months and the median OS was 15.1 months versus 12.6 months (Arm A vs. Arm B, respectively). Grade 3-4 neutropenia was 39 versus 40 %, febrile neutropenia 6 versus 17 %, nausea/vomiting 3 versus 20 %, and toxicity-related hospitalization 30 versus 53 % (Arm A vs. Arm B, respectively). The authors concluded that the de Gramont-based DCF is an active and tolerable three-drug regimen.
Considering that the aim of treatment in metastatic disease is palliation, great importance should be given to the convenience and tolerability of the treatment. With only one 5-FU bolus and a 46-h infusion of 5-FU, our regimen appears easier and more convenient to administer than the standard [24] and dose-dense DCF regimens [34] and may increase the quality of life because of the short treatment duration. In our regimen, the dosages of docetaxel and cisplatin are lower than those dosages in the standard and dose-dense DCF regimens, which explains the low toxicity profile of our regimen.
Currently, many other studies that tested the different DCF regimens have been published [37] [38] [39] [40] [41] [42] [43] [44] [45] . The standard DCF regimen used by Van Cutsem et al. was a 5-day regimen. This regimen consisted of docetaxel at a dose of 75 mg/m 2 and cisplatin at a dose of 75 mg/m 2 on day 1 plus 5-FU at a dose of 750 mg/m 2 /day as a continuous infusion on days 1 to 5, every 3 weeks [24] . Compared to the standard DCF regimen, requiring the patient to carry a 5-day continuous infusion pump once in each 21 days [24] , our modified DCF regimen, which requires carrying a 2-day continuous infusion pump once in each 14 days, could be considered as a more convenient treatment. A 3-day continuous infusion schedule of 5-FU to reduce the infusion days of chemotherapy has been shown to be an active and tolerable regimen as a first-line treatment in patients with AGC [38] . A split-dose DCF regimen, with biweekly scheduling of docetaxel and cisplatin combined with weekly 5-FU and LV, has also been shown to be an active treatment with favorable toxicity profile in AGC [37] . Subsequent attempts have been tried to improve the tolerability of the DCF regimen by reducing or fractionating the doses of cisplatin and docetaxel [38] [39] [40] [41] [42] . Monthly DCF regimens [43] and weekly DCF regimens [44, 45] have been investigated as first-line therapy in patients with AGC. The results of these studies suggest that modification of the standard DCF schedule may yield a regimen with an improved safety profile, without compromising the efficacy of the regimen [38] [39] [40] [41] [42] [43] [44] [45] .
In summary, our results show that a de Gramont-based DCF regimen may have tolerable toxicities and be an effective and convenient palliative treatment of AGC. It may provide an alternative regimen to the standard DCF. Because of the bimonthly 2-day infusion schedule with only one 5-FU bolus, this regimen can be administered on an outpatient basis without disrupting daily life. Future trials of palliative chemotherapy for AGC using the de Gramont-based DCF regimen are needed.
